Table 3 Uni-and multi-variate analyses of patients’ factors affecting social reintegration.

From: Higher exercise tolerance early after allogeneic hematopoietic stem cell transplantation is the predictive marker for higher probability of later social reintegration

Variables

Univariate

Multivariate

OR (95%CI)

p

OR (95%CI)

p

Pre- and post-HSCT characteristics

Sex

Female

0.27 (0.76–0.98)

0.04*

0.07 (0.01–0.54)

0.01*

Age

40 y or over

0.61 (0.18–2.10)

0.43

  

BMI

 < mean

0.75 (0.19–2.95)

0.68

  

PS

2–4

0.11 (0.01–1.16)

0.67

  

HCT-CI

2-

0.23 (0.60–0.94)

0.04*

0.10 (0.01–0.84)

0.03*

Diagnosis

AML

1.00 (reference)

   
 

MDS

0.76 (0.16–3.51)

0.73

  
 

ALL

0.94 (0.26–3.30)

0.92

  
 

ML

0.63 (0.15–2.56)

0.52

  

Stem cell source

Rel-BM

1.00 (reference)

   
 

Rel-PB

2.64 (0.29–23.9)

0.38

  
 

UR-BM

0.48 (0.14–1.57)

0.22

  
 

CB

1.62 (0.47–5.55)

0.43

  

Disease status

nCR

0.63 (0.17–2.32)

0.49

  

Conditioning

MAC

0.69 (0.18–2.56)

0.58

  

aGVHD

Gr2-4

1.11 (0.33–3.66)

0.86

  

Variables at discharge

Hospitalized period

 > median

0.65 (0.26–1.60)

0.34

  

BMI

 < mean

1.42 (0.44–4.56)

0.55

  

PS

2–4

0.42 (0.16–1.06)

0.06

0.65 (0.02–19.3)

0.80

Hgb

 < mean

0.37 (0.10–1.28)

0.10

0.27 (0.04–1.83)

0.18

TP

 < mean

0.56 (0.16–1.91)

0.35

  

Alb

 < mean

0.40 (0.12–1.36)

0.14

0.57 (0.11–3.03)

0.51

CRP

 < mean

0.86 (0.26–2.76)

0.79

  

Evaluation for physical function at discharge

KES (per 0.5Nm/kg change)

 

1.33 (0.87–2.01)

 0.17

  

∆KES (per 5% change)

 

1.00 (0.90–1.09)

0.96

0.94 (0.80–1.10)

 0.46

6MWD (per 5 m change)

 

1.04 (1.00–1.08)

 0.02*

  

∆6MWD (per 5% change)

 

1.28 (1.03–1.58)

0.02*

1.47 (1.01–2.15)

 0.04*

  1. OR; odds ratio, CI; confidence interval, HSCT; hematopoietic stem cell transplantation, BMI; body mass index, PS; performance status, HCT-CI; hematopoietic cell transplantation comorbidity index, AML; acute myeloid leukemia, MDS; myelodysplastic syndrome, ALL; acute lymphoblastic leukemia, ML; malignant lymphoma, Rel; related, UR; unrelated, BM; bone marrow, PB; peripheral blood, CB; cord blood, nCR; non complete remission, MAC; myeloablative conditioning, aGVHD; acute graft-versus-host disease, BMI; body mass index, PS; performance status, Hgb; hemoglobin, TP; serum total protein, Alb; serum albumin, and CRP; C-reactive protein, KES; knee extensor strength, and 6MWD; 6-min walking distance. ∆ indicates difference between pre- and post-HSCT. * indicates statistically significant.
Back to article page